Dr. Daria Mochly-Rosen is a Professor of Chemical and Systems Biology at Stanford University where she leads multi-disciplinary research on the molecular mechanisms of diseases.
She has published more than 290 papers and holds over 50 patents. She has founded three biotech companies, including KAI Pharmaceuticals (acquired by Amgen in 2012) and initiated several clinical trials.
Her experience in translating basic research into successful drug development projects led her to found SPARK, Stanford’s translational research program, in 2006.
The SPARK model has now been adopted in currently more than 70 institutes on all continents and she serves as President and Founder of the SPARK GLOBAL organization.
In this webinar she will share with us her story on translating her research discoveries into therapeutics, giving insights into:
- the countless lessons she has learned from her own translational effort
- how her experience led to the establishment of the SPARK program
- how SPARK has helped other projects to advance research discoveries from bench to bedside world-wide.
If you face problems with the registration link, please use the direct link (Meeting Registration - Zoom)
The webinar will be hosted by SPARK Finland at Tampere Universitie’s Zoom. Note that the number of participants is limited, therefore register asap!
SPARK Europe is the joint network of SPARK sites all over Europe including Israel: SPARK-BIH, SPARK Finland, SPARK FLI, SPARK Poland and SPARK Tel Aviv.
European SPARK programs are members of SPARK Global network.
The purpose of SPARK programs is to provide the education and mentorship necessary to advance research discoveries from the bench to the bedside, hence to increase the maturity of academic and clinical discoveries towards practical solutions that address unmet need in the life science and health tech space.
The program follows the same principles that have been the cornerstones of SPARK at Stanford since it was established by Professor Daria Mochly-Rosen and Kevin Grimes in 2006 for advancing new biomedical research discoveries into promising new treatments for patients.